Xenon Pharmaceuticals’ (XENE) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Xenon Pharmaceuticals (NASDAQ:XENE) in a research report report published on Wednesday,Benzinga reports. HC Wainwright currently has a $53.00 price target on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Xenon Pharmaceuticals’ Q1 2025 earnings at ($0.88) EPS, Q2 2025 earnings at ($0.89) EPS, Q3 2025 earnings at ($0.90) EPS and Q4 2025 earnings at ($0.91) EPS.

Other equities research analysts have also issued reports about the company. Raymond James reaffirmed an “outperform” rating and issued a $50.00 price objective on shares of Xenon Pharmaceuticals in a research note on Thursday, October 10th. Needham & Company LLC restated a “buy” rating and set a $60.00 price target on shares of Xenon Pharmaceuticals in a research note on Wednesday. Wedbush reduced their price objective on shares of Xenon Pharmaceuticals from $50.00 to $49.00 and set an “outperform” rating for the company in a research note on Friday, August 9th. Cantor Fitzgerald restated an “overweight” rating and issued a $65.00 price target on shares of Xenon Pharmaceuticals in a report on Friday, August 9th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $55.00 price objective on shares of Xenon Pharmaceuticals in a research report on Tuesday, September 3rd. Eleven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $57.45.

Xenon Pharmaceuticals Price Performance

Shares of NASDAQ XENE opened at $39.83 on Wednesday. The firm has a fifty day moving average price of $41.18 and a 200-day moving average price of $40.36. The stock has a market cap of $3.04 billion, a PE ratio of -14.21 and a beta of 1.25. Xenon Pharmaceuticals has a 1 year low of $28.10 and a 1 year high of $50.99.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.01. During the same quarter in the prior year, the business posted ($0.73) EPS. On average, research analysts expect that Xenon Pharmaceuticals will post -3.1 EPS for the current year.

Hedge Funds Weigh In On Xenon Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. FMR LLC increased its holdings in Xenon Pharmaceuticals by 2.2% in the third quarter. FMR LLC now owns 6,917,684 shares of the biopharmaceutical company’s stock valued at $272,349,000 after buying an additional 149,511 shares in the last quarter. Driehaus Capital Management LLC boosted its stake in Xenon Pharmaceuticals by 2.3% during the second quarter. Driehaus Capital Management LLC now owns 4,419,472 shares of the biopharmaceutical company’s stock worth $172,315,000 after buying an additional 97,732 shares during the last quarter. Wellington Management Group LLP increased its position in Xenon Pharmaceuticals by 0.4% during the third quarter. Wellington Management Group LLP now owns 3,843,447 shares of the biopharmaceutical company’s stock worth $151,317,000 after purchasing an additional 15,226 shares during the last quarter. Braidwell LP increased its holdings in shares of Xenon Pharmaceuticals by 5.7% during the 3rd quarter. Braidwell LP now owns 2,707,255 shares of the biopharmaceutical company’s stock worth $106,585,000 after buying an additional 146,682 shares during the last quarter. Finally, Janus Henderson Group PLC increased its stake in Xenon Pharmaceuticals by 144.2% during the third quarter. Janus Henderson Group PLC now owns 2,552,392 shares of the biopharmaceutical company’s stock worth $100,506,000 after acquiring an additional 1,507,135 shares during the last quarter. Institutional investors and hedge funds own 95.45% of the company’s stock.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.